GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Austar Lifesciences Ltd (HKSE:06118) » Definitions » Forward PE Ratio

Austar Lifesciences (HKSE:06118) Forward PE Ratio : 0.00 (As of May. 17, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Austar Lifesciences Forward PE Ratio?

Austar Lifesciences's Forward PE Ratio for today is 0.00.

Austar Lifesciences's PE Ratio without NRI for today is 0.00.

Austar Lifesciences's PE Ratio for today is 0.00.


Austar Lifesciences Forward PE Ratio Historical Data

The historical data trend for Austar Lifesciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Austar Lifesciences Forward PE Ratio Chart

Austar Lifesciences Annual Data
Trend
Forward PE Ratio

Austar Lifesciences Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Austar Lifesciences's Forward PE Ratio

For the Medical Devices subindustry, Austar Lifesciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Austar Lifesciences's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Austar Lifesciences's Forward PE Ratio falls into.



Austar Lifesciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Austar Lifesciences  (HKSE:06118) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Austar Lifesciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Austar Lifesciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Austar Lifesciences (HKSE:06118) Business Description

Traded in Other Exchanges
Address
No. 1018, Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is a China-based company engaged in providing engineering solutions to pharmaceutical manufacturers and research institutes. The business activity of the group is operated through Liquid and Bioprocess Systems; Clean Room and Automation Control and Monitoring Systems; Powder and Solid Systems; Good Manufacturing Practice (GMP) Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It derives the majority of revenue from the Liquid and Bioprocess System segment which is involved in providing solutions in pharmaceutical and water systems to treat water. The geographical business presence of the firm is seen across China and in other countries.

Austar Lifesciences (HKSE:06118) Headlines

No Headlines